Euronews is no longer accessible on Internet Explorer. This browser is not updated by Microsoft and does not support the last technical evolutions. We encourage you to use another browser, such as Edge, Safari, Google Chrome or Mozilla Firefox.
BREAKING NEWS

GSK's HIV drug receives EU marketing nod

GSK's HIV drug receives EU marketing nod
FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. REUTERS/Loriene Perera/File Photo -
Copyright
Loriene Perera(Reuters)
Euronews logo
Text size Aa Aa

(Reuters) – GlaxoSmithKline <GSK.L> said its specialist HIV company had received marketing authorisation from the European Commission for its drug to treat advanced stage HIV infections in adults and adolescents above the age of 12 and weighing at least 40 kg.

ViiV Healthcare, which is majority owned by GSK and with Pfizer Inc <PFE.N> and Shionogi Ltd as shareholders, got the U.S. Food and Drug Administration approval for the treatment Dovato in April.

(Reporting by Noor Zainab Hussain in Bengaluru; editing by Gopakumar Warrier)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.